Definition and estimation of osteonecrosis of jaw (ONJ), and optimal duration of antiresorptive treatment in bone metastatic cancer patients: supplementary data from the denosumab extension study?

Support Care Cancer. 2017 Feb;25(2):345-349. doi: 10.1007/s00520-016-3147-9. Epub 2016 Mar 9.

Authors

Vittorio Fusco¹, Alberto Bedogni², Alfredo Addeo³, Giuseppina Campisi⁴

Affiliations

¹ Oncology Unit, SS Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy. vittoriofusco1@tin.it.
² Unit of Maxillofacial Surgery, Department of Neurosciences - DNS, University of Padua, Padua, Italy.
³ Bristol Cancer Institute, University Hospitals Bristol NHS, Bristol, UK.
⁴ Department of Surgical, Oncology and Oral Sciences - Sector of Oral Medicine, Palermo University, Palermo, Italy.

PMID: 26961666
DOI: 10.1007/s00520-016-3147-9

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Bisphosphonate-Associated Osteonecrosis of the Jaw
Bone Density Conservation Agents
Denosumab*
Diphosphonates
Humans
Jaw Diseases
Neoplasms
Osteonecrosis*

Substances

Bone Density Conservation Agents
Diphosphonates
Denosumab